Incretin-FGF21 fusion molecule maximizes metabolic effects in mice  

作　　者：Yulin Kong Shenglong Zhu Yong Q.Chen 

机构地区：[1]Department of Urology,Jiangnan University Medical Center,Wuxi 214122,China [2]Wuxi School of Medicine,Jiangnan University,Wuxi 214122,China

出　　处：《Acta Biochimica et Biophysica Sinica》2024年第1期144-147,共4页生物化学与生物物理学报（英文版）

摘　　要：Common metabolic diseases,such as obesity and nonalcoholic steatohepatitis(NASH),are major public health concerns.The only therapeutic approach that offers weight loss of 20%or more is bariatric surgery.Medications are now available,such as liraglutide(Victoza),dulaglutide(Trulicity)and semaglutide(Ozempic)which are gut hormone incretin memetics[1].Noticeably,the glucosedependent insulinotropic polypeptide receptor(GIPR)/glucagonlike peptide 1 receptor(GLP-1R)dual agonist tirzepatide(Mounjaro)attains a greater than 20%reduction in body weight[2].Therefore,incretin receptor agonists are being extensively explored[1].

关 键 词：DISEASES SURGERY OBESITY 

分 类 号：R589[医药卫生—内分泌]